Tegoprubart (AT-1501) is an experimental humanized monoclonal antibody that inhibits CD40L. It is developed for ALS and transplant rejection.
Eledon Pharmaceuticals In March 2026, clinical data presented at the Advanced Technologies and Treatments for Diabetes (ATTD) conference demonstrated that tegoprubart, a monoclonal antibody inhibiting the CD40 ligand, enabled 100% insulin independence in ten evaluable patients following allogeneic islet transplantation. The pilot study, conducted at the University of Chicago Medicine, utilized tegoprubart as part of a calcineurin inhibitor-free regimen, resulting in a mean HbA1c of 5.35% without evidence of nephrotoxicity or neurotoxicity typically associated with standard immunosuppressants.
References
